{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T11:09:19Z","timestamp":1720609759191},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1157\/13126266","type":"journal-article","created":{"date-parts":[[2008,11,22]],"date-time":"2008-11-22T18:15:16Z","timestamp":1227377716000},"page":"7-12","source":"Crossref","is-referenced-by-count":0,"special_numbering":"S8","title":["Datos cl\u00ednicos I. Experiencia cl\u00ednica de tenofovir en combinaciones con inhibidores no an\u00e1logos de la transcriptasa inversa"],"prefix":"10.1016","volume":"26","author":[{"given":"Jos\u00e9 Ignacio Bernardino","family":"de la Serna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta Mora","family":"Rillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Ram\u00f3n Arribas","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1157\/13126266_bib1","unstructured":"European Medicines Agency. Comit\u00e9 de medicamentos de uso humano (CHMP). Informe Europeo p\u00fablico de autorizaci\u00f3n (EPAR) (accedido, 4 Mar 2008). Disponible en: http:\/\/www.emea.europa.eu\/humandocs\/PDFs \/EPAR\/viread\/351001en6.pdf"},{"key":"10.1157\/13126266_bib2","unstructured":"Recomendaciones de GESIDA\/Plan Nacional sobre el SIDA respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana. Actualizaci\u00f3n enero 2008 (accedido, 7 Mar 2008). Disponible en: http:\/\/www.gesida.seimc.org\/index.asp"},{"key":"10.1157\/13126266_bib3","unstructured":"Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 29, 2008;1-128 (accedido 7 Mar 2008). Disponible en: http:\/\/www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf"},{"key":"10.1157\/13126266_bib4","unstructured":"European AIDS Clinical Society (EACS). Guidelines for the clinical management and treatment on HIV infected adults in Europe. Versi\u00f3n 2. Diciembre 2007 (accedido 7 Mar 2008). Disponible en: http:\/\/www.eacs.eu\/guide\/index. htm"},{"key":"10.1157\/13126266_bib5","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/135965350501000117","article-title":"Early virological failure with a combination of tenofovir, didanosine and efavirenz","volume":"10","author":"Podzamczer","year":"2005","journal-title":"Antiviral Therapy"},{"key":"10.1157\/13126266_bib6","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1097\/01.aids.0000176218.40861.14","article-title":"Early virologic failure in HIV-1 infected subjects on didanosine\/tenofovir\/efavirenz: 12 week results from a randomized trial","volume":"19","author":"Maitland","year":"2005","journal-title":"AIDS"},{"key":"10.1157\/13126266_bib7","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1177\/135965350501000405","article-title":"Early virological failure alter tenofovir + didanosine + efafirenz combination in HIV-positive patients upon starting antirretroviral therapy","volume":"10","author":"Torti","year":"2005","journal-title":"Antiviral Therapy"},{"key":"10.1157\/13126266_bib8","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1310\/hct0804-221","article-title":"Comparative efficacy of nucleoside\/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview","volume":"8","author":"Barlett","year":"2007","journal-title":"HIV Clin Trials"},{"key":"10.1157\/13126266_bib9","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral naive patients: a 3-year randomized trial","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"issue":"Suppl 1","key":"10.1157\/13126266_bib10","article-title":"Similar 96-week efficacy profile regardless of baseline characteristic variable for tenofovir disoproxil fumarate (tdf) versus stavudine (d4t) when used in combination with lamivudine and efavirenz in antiretroviral naive patients","volume":"8","author":"Pozniak","year":"2003","journal-title":"Antivir Ther"},{"key":"10.1157\/13126266_bib11","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/01.qai.0000221690.54349.83","article-title":"Renal safety of tenofovir disoproxil fumarate in HIV-1 treatment-experienced patients with adverse events related to prior NRTI use: data from a prospective, observational, multicenter study","volume":"42","author":"Moreno","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1157\/13126266_bib12","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1086\/428840","article-title":"Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment","volume":"40","author":"Gallant","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13126266_bib13","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/ndt\/gfh658","article-title":"Team Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-na\u00efve HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study","volume":"20","author":"Izzedine","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1157\/13126266_bib14","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1468-1293.2006.00404.x","article-title":"Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoroxil fumarate or stavudine with lamivudine and efavirenz in study 903","volume":"7","author":"Margot","year":"2006","journal-title":"HIV Medicine"},{"key":"10.1157\/13126266_bib15","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1310\/hct0806-381","article-title":"The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in HIV-1-infected patients: three-year follow-up after switching therapy","volume":"8","author":"Valdez","year":"2007","journal-title":"HIV Clin Trials"},{"key":"10.1157\/13126266_bib16","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa051871","article-title":"Tenofovir DF, emtricitabine and efavirenz vs. zidovudine, lamivudine and efavirenz for VIH","volume":"354","author":"Gallant","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1157\/13126266_bib17","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/01.qai.0000245886.51262.67","article-title":"Tenofocir disoproxil fumarate, emtricitabine, and efavirenz versus fixed dose zidovudine\/lamivudine and efavirenz in antirretroviral-naive patients. Virologic, immunologic, and morphologic changes: a 96-week analysis","volume":"43","author":"Pozniak","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1157\/13126266_bib18","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/QAI.0b013e31815acab8","article-title":"Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine\/lamivudine and efavirenz in treatment-naive patients: 144-week analysis","volume":"47","author":"Arribas","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1157\/13126266_bib19","unstructured":"European Medicines Agency. Comit\u00e9 de medicamentos de uso humano (CHMP). Informe Europeo p\u00fablico de autorizaci\u00f3n (EPAR) (accedido 4 Mar 2008). Disponible en: http:\/\/www.emea.europa.eu\/humandocs\/Humans\/EPAR\/atripla\/atripla.htm"},{"key":"10.1157\/13126266_bib20","series-title":"11th European AIDS Conference","article-title":"Final week 144 resistance analysis of study 934: no K65R detected and lower frequency of M184V on tenofovir DF + emtricitabine + efavirenz compared to combivir + efavirenz","author":"Mc Coll","year":"2007"},{"key":"10.1157\/13126266_bib21","series-title":"14th Conference on retroviruses and opportunistic infections","first-page":"503","article-title":"Early virologic non-response to once daily combination of lamivudine, tenofovir and nevirapine in ART-na\u00efve HIV-infected patients: preliminary results of the DAUFIN study","author":"Rey","year":"2007"},{"key":"10.1157\/13126266_bib22","series-title":"11th European AIDS Conference","article-title":"Risk of early virological failure to tenofovir\/emtricitabine once daily plus nevirapine twice daily in HIV-infected patients na\u00efve to antiretroviral therapy","author":"Lapadula","year":"2007"},{"key":"10.1157\/13126266_bib23","series-title":"11th European AIDS Conference","article-title":"Virologic supresi\u00f3n is mantained alter change to efavirenz\/emtricitabine\/tenofovir disoproxil fumarate single tablet regimen (EFV\/FTC\/EFV) vs continuation of current antirretroviral therapy: Study AI266073 results of 24 week interim analyses","author":"DeJes\u00fas","year":"2007"}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X0876525X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X0876525X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,21]],"date-time":"2023-05-21T08:11:58Z","timestamp":1684656718000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X0876525X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":23,"alternative-id":["S0213005X0876525X"],"URL":"https:\/\/doi.org\/10.1157\/13126266","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}